ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study

被引：0
|
作者：
Shen, Jingnan
Guo, Wei
Wang, Jin
Xie, Xianbiao
Xie, Lu
Xu, Jie
Jing, Chen
Lin, Jianhua
Li, Xianan
Zhou, Yong
Wang, Guowen
Zhang, Xiaojing
Yao, Weitao
Dong, Yang
Ye, Zhaoming
Wang, Li
Zeng, Yanyan
Wu, Yongyong
Yang, Xiugao
Zhang, Yanfeng
机构：
[1] Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[2] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[4] Sun Yat sen Univ, Dept Musculoskeletal, Affiliated Hosp 1, Oncol Ctr, Guangzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China
[6] Fujian Med Univ, Dept Orthoped, Affiliated Hosp 1, Fuzhou, Peoples R China
[7] Hunan Canc Hosp, Changsha, Peoples R China
[8] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Peoples R China
[9] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[10] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[11] Zhengzhou Univ, Henan Canc Hosp, Dept Orthoped, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[12] Shanghai Sixth Peoples Hosp, Shanghai, Peoples R China
[13] Zhejiang Univ, Dept Orthoped, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
[14] CSPC Pharmaceut Grp Ltd, Shanghai, Peoples R China
[15] CSPC Pharmaceut Grp Ltd, Beijing, Peoples R China
[16] AlaMab, Phoenixville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11530
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
    Chen, Zhiwei
    Shen, Shengping
    Shi, Wenbo
    Jiang, Gening
    Wang, Xin
    Jian, Hong
    Zhou, Zhen
    Ding, Zhengping
    Lu, Shun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6543 - 6552
  • [32] Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study
    Jin, Jie
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Zhou, Hu
    Gao, Sujun
    Wang, Wei
    Dang, Huibing
    Chen, Yuqing
    Wang, Jishi
    Zhao, Peng
    Yang, Haiping
    Ma, Liangming
    Zhao, Qingwei
    Suo, Shanshan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
    Zhang, L.
    Yang, Y.
    Chen, X.
    Li, J.
    Pan, J.
    He, X.
    Lin, L.
    Shi, Y.
    Feng, W.
    Xiong, J.
    Yang, K.
    Yu, Q.
    Hu, D.
    Sun, Y.
    Zhang, Q.
    Hu, G.
    Li, P.
    Shen, L.
    Yang, Q.
    Zhang, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S659 - S659
  • [34] A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on θ2 lines of chemotherapy: CAPTAIN study
    Zhang, L.
    Yang, Y.
    Chen, X.
    Li, J.
    Pan, J.
    He, X.
    Lin, L.
    Shi, Y.
    Feng, W.
    Xiong, J.
    Yang, K.
    Yu, Q.
    Hu, D.
    Sun, Y.
    Zhang, Q.
    Hu, G.
    Li, P.
    Shen, L.
    Yang, Q.
    Zhang, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1348 - S1349
  • [35] A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens
    Huang, Yan
    Zhang, Li
    Pan, Jian-ji
    Hu, Guoqing
    Gang, Wu
    Xiong, Jian Ping
    Hu, Chaosu
    Lin, Lizhu
    Yu, Hao
    Jiang, Haoyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
    Xie, Lu
    Xu, Jie
    Sun, Xin
    Guo, Wei
    Gu, Jin
    Liu, Kuisheng
    Zheng, Bingxin
    Ren, Tingting
    Huang, Yi
    Tang, Xiaodong
    Yan, Taiqiang
    Yang, Rongli
    Sun, Kunkun
    Shen, Danhua
    Li, Yuan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [37] AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study
    Bi, Nan
    Liu, Fang
    Hu, Ying
    Wang, Wei
    Liu, Wenyang
    Liu, Rongrui
    Liu, Yanli
    Zhang, Pei
    Zhao, Chuan Hua
    Chen, Jing
    Luo, Lingrong
    Huang, Zaijie
    Gu, Mengjie
    Tang, Kaiyang
    Lu, Xuyang
    Song, Xuyang
    Zhao, Tianyi
    Wang, Yuan
    Liang, Hongming
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study (vol 31, pg 5340, 2024)
    Zager, Jonathan S.
    Orloff, Marlana
    Ferrucci, Pier Francesco
    Choi, Junsung
    Eschelman, David J.
    Glazer, Evan S.
    Ejaz, Aslam
    Howard, J. Harrison
    Richtig, Erika
    Ochsenreither, Sebastian
    Reddy, Sunil A.
    Lowe, Michael C.
    Beasley, Georgia M.
    Gesierich, Anja
    Bender, Armin
    Gschnell, Martin
    Dummer, Reinhard
    Rivoire, Michel
    Arance, Ana
    Fenwick, Stephen William
    Sacco, Joseph J.
    Haferkamp, Sebastian
    Weishaupt, Carsten
    John, Johnny
    Wheater, Matthew
    Ottensmeier, Christian H.
    ANNALS OF SURGICAL ONCOLOGY, 2024, : 8262 - 8263
  • [39] A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1
    Hu, Xiaojie
    Wang, Jinhu
    Li, Wenbin
    Zeng, Kang
    Li, Yanling
    Tao, Juan
    Guan, Zhonghai
    Kang, Zhuang
    Xu, Zhongyuan
    Li, Changxing
    Ma, Yaohui
    Yang, Liu
    Wu, Zhuli
    Han, Pu
    Lin, Hongmei
    Li, Ben
    Hui, Ai-Min
    Wang, Xingli
    Lin, Xiaoxi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma Including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study
    Shi, Guoming
    Huang, Xiaoyong
    Wen, Tianfu
    Song, Tianqiang
    Kuang, Ming
    Mou, Haibo
    Bao, Lequn
    Zhao, Haitao
    Zhao, Hong
    Feng, Xielin
    Zhang, Bixiang
    Peng, Tao
    Zhang, Yubao
    Li, Xiangcheng
    Yu, Hongsheng
    Cao, Yu
    Luo, Yang
    Chen, Ye
    Chen, Mingxia
    Fan, Jia
    Zhou, Jian
    CANCER RESEARCH, 2023, 83 (08)
12345